CNX vs. CERE, HCC, ARCH, HNRG, OVV, PR, APA, CHK, AR, and HESM
Should you be buying CNX Resources stock or one of its competitors? The main competitors of CNX Resources include Cerevel Therapeutics (CERE), Warrior Met Coal (HCC), Arch Resources (ARCH), Hallador Energy (HNRG), Ovintiv (OVV), Permian Resources (PR), APA (APA), Chesapeake Energy (CHK), Antero Resources (AR), and Hess Midstream (HESM).
Cerevel Therapeutics (NASDAQ:CERE) and CNX Resources (NYSE:CNX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.
In the previous week, CNX Resources had 3 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 14 mentions for CNX Resources and 11 mentions for Cerevel Therapeutics. CNX Resources' average media sentiment score of 0.76 beat Cerevel Therapeutics' score of 0.46 indicating that Cerevel Therapeutics is being referred to more favorably in the media.
CNX Resources received 662 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. Likewise, 70.55% of users gave CNX Resources an outperform vote while only 66.52% of users gave Cerevel Therapeutics an outperform vote.
87.7% of Cerevel Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of CNX Resources shares are owned by institutional investors. 5.1% of Cerevel Therapeutics shares are owned by insiders. Comparatively, 3.1% of CNX Resources shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
CNX Resources has a net margin of 40.44% compared to CNX Resources' net margin of 0.00%. Cerevel Therapeutics' return on equity of 7.68% beat CNX Resources' return on equity.
Cerevel Therapeutics presently has a consensus target price of $42.67, suggesting a potential downside of 4.25%. CNX Resources has a consensus target price of $25.57, suggesting a potential upside of 1.43%. Given Cerevel Therapeutics' higher possible upside, analysts clearly believe CNX Resources is more favorable than Cerevel Therapeutics.
CNX Resources has higher revenue and earnings than Cerevel Therapeutics. Cerevel Therapeutics is trading at a lower price-to-earnings ratio than CNX Resources, indicating that it is currently the more affordable of the two stocks.
Cerevel Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, CNX Resources has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.
Summary
CNX Resources beats Cerevel Therapeutics on 12 of the 16 factors compared between the two stocks.
Get CNX Resources News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CNX Resources Competitors List
Related Companies and Tools
